eFFECTOR Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:eFFECTOR Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11276
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
eFFECTOR Therapeutics Inc (eFFECTOR) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of selective translation regulators for the treatment of cancer. Its investigational compounds are designed to restore the translational control of processes that tumors are hijacked to their benefit, preserving normal cell function. The company’s pipeline programs include tomivosertib (eFT508), a MNK1/2 inhibitor intended for the treatment of patients with solid tumors and lymphoma. It also develops selective translation regulator programs, including eIF4E, an oncogenic and historically intractable target for a variety of human cancers; and eFT226, for lymphoma. eFFECTOR is headquartered in San Diego, California, the US.

eFFECTOR Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
Partnerships 19
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc – Key Competitors 21
eFFECTOR Therapeutics Inc – Key Employees 22
eFFECTOR Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Mar 23, 2018: eFFECTOR Announces Appointment of John W. Smither to its Board of Directors 24
Product Approvals 25
Mar 09, 2017: Effector Therapeutics Lead Product Candidate, EFT508, Receives Orphan Designation From FDA for Treatment of Diffuse Large B-cell Lymphoma 25
Clinical Trials 26
Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combination with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone 26
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma 27
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer 28
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry 29
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting 30
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile 31
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects 32
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer 33
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017 35
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc, Key Competitors 21
eFFECTOR Therapeutics Inc, Key Employees 22

List of Figures
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[eFFECTOR Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NV Bekaert SA:企業の戦略・SWOT・財務情報
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Fluor Corp (FLR):電力:M&Aディール及び事業提携情報
    Summary Fluor Corp (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other services t …
  • ING Life Insurance Company Korea, Ltd.:企業の戦略・SWOT・財務情報
    ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Daido Steel Co., Ltd.:企業の戦略・SWOT・財務分析
    Daido Steel Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daido Steel Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Myriad Group AG:企業の戦略的SWOT分析
    Myriad Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Parkson Retail Group Ltd:企業の戦略・SWOT・財務情報
    Parkson Retail Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Parkson Retail Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Veikkaus Oy:企業の戦略的SWOT分析
    Veikkaus Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Golden Valley Mines Ltd. (GZZ):企業の財務・戦略的SWOT分析
    Golden Valley Mines Ltd. (GZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • TWC Enterprises Limited:戦略・SWOT・企業財務分析
    TWC Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary TWC Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Quadrise Fuels International Plc (QFI):企業の財務・戦略的SWOT分析
    Quadrise Fuels International Plc (QFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Arthrex Inc:企業の戦略的SWOT分析
    Arthrex Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bank Muscat:企業の戦略・SWOT・財務分析
    Bank Muscat - Strategy, SWOT and Corporate Finance Report Summary Bank Muscat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Quizno’s Master LLC:企業の戦略・SWOT・財務情報
    The Quizno’s Master LLC - Strategy, SWOT and Corporate Finance Report Summary The Quizno’s Master LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Santos Ltd (STO):企業の財務・戦略的SWOT分析
    Santos Ltd (STO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rich Pharmaceuticals Inc (RCHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Rich Pharmaceuticals Inc (Rich Pharmaceuticals) is a biopharmaceutical company that offers discovery and development of therapies for the treatment of acute myelogenous leukemia (AML) in refractory patients. The company’s pipeline portfolio offers a lead drug candidate for the treatment of a …
  • NuVasive Inc (NUVA):医療機器:M&Aディール及び事業提携情報
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • Polarcus Ltd (PLCS):石油・ガス:M&Aディール及び事業提携情報
    Summary Polarcus Ltd (Polarcus) is a marine geophysical company that provides towed streamer data acquisition and imaging services. The company provides marine acquisition services such as vessel specifications, increasing efficiency, managing emissions to air, managing emissions to sea, polar code …
  • Bharat Dynamics Limited
    Bharat Dynamics Limited - Strategy, SWOT and Corporate Finance Report Summary Bharat Dynamics Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • TransCanada Corp:企業の戦略・SWOT・財務情報
    TransCanada Corp - Strategy, SWOT and Corporate Finance Report Summary TransCanada Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆